Combination Chemotherapy Treatments in Patients With Metastatic Colorectal Cancer
Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
This study will examine a new combination of drugs: celecoxib, capecitabine and irinotecan,
for the treatment of metastatic colorectal cancer. Capecitabine and irinotecan, individually,
are approved by the Food and Drug Administration (FDA) for use in colorectal cancer. The
combination of these two drugs is experimental (not approved by the FDA as standard
treatment), but is a widely used treatment option and preliminary studies have shown that
treatment with the combination of capecitabine and irinotecan has a positive effect on
metastatic colorectal cancer. Likewise, previous research in animals has shown that
celecoxib, a drug approved for arthritis therapy, also has activity against this tumor type
and may improve the anti-cancer activity of the combination of capecitabine and irinotecan.
Phase:
Phase 2
Details
Lead Sponsor:
University of Michigan Cancer Center University of Michigan Rogel Cancer Center